Forming Global Alliances to Cure Diabetes
Scientific collaboration has long been at the core of the Diabetes Research Institute’s philosophy. By forming partnerships and sharing resources with the brightest scientists across the globe, we’ll achieve our goal: to bring promising findings to diabetes patients more quickly than ever before. Our philosophy of collaboration takes many forms:
- We’ve assembled a formal alliance of researchers that is unprecedented in size and scope. Our Diabetes Research Institute Federation unites top researchers from a dozen medical centers in 10 countries with one goal: to cure diabetes.
- Several of our DRI researchers are part of the national leadership of Trial Net. Funded by The National Institutes of Health (NIH), this program enables researchers around the world to perform intervention studies aimed at preserving insulin-producing cells in individuals with newly-onset diabetes, or in those at risk of developing the disease.
- One of our DRI researchers is a member of the Type 1 Diabetes Genetics Consortium (T1DGC), the official liaison with the International Histocompatibility Working Group, and a member of the Technology Development Sub-Committee of the T1DGC.
- The DRI collaborates with other researchers through the Clinical Islet Transplantation Consortium, a network of clinical centers, and a data-coordinating center, established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.
- The current Good Manufacturing Process (cGMP) cell processing team for the DRI performed the first successful human islet cell transplant in Asia.
Jeffrey Hubbell, Ph.D., of the Ecole Polytechnique Fédérale de Lausanne, Switzerland
Alternate Content Title
Alternate content supporting alternate title